Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-12-12
2011-11-29
Carlson, Karen (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C530S350000
Reexamination Certificate
active
08067357
ABSTRACT:
The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins, and the administration of complexes comprising of pharmaceutical or diagnostic compounds coupled to a compound B recognizing and binding to compound A to subjects. The compositions include annexins, annexin variants, that are not internalized by the target cells, derivatives thereof, and complexes thereof.
REFERENCES:
patent: 7511016 (2009-03-01), Reutelingsperger
patent: 2006/0024315 (2006-02-01), Schnitzer et al.
patent: WO 2006/003488 (2006-01-01), None
Clemen et al. 2001; Annexin VII; an astroglial protein exhibiting a Ca2+-dependent subcellular distribution. NeuroReport 12(6): 1139-1144.
Mira, et al., “Inhibition of Cytosolic Phospholipase A2 by Annex in V in Differentiated Permeabilized HL-60 Cells. Evidence of Crucial Importance of Domain I Type II Ca2+-Binding Site in the Mechanism of Inhibition,”Journal of Biological Chemistry,Apr. 18, 1997, vol. 272, No. 16, pp. 10474-10482.
Kenis, et al., “Cell Surface-Expressed Phosphatidylserine and Annexin A5 Open a Novel Portal of Cell Entry,”Journal of Biological Chemistry,Dec. 10, 2004, vol. 279, No. 50, pp. 52623-52629.
Huber, et al., “The Crystal and Molecular Structure of Human Annexin V, an Anticoagulant Protein that Binds to Calcium and Membranes,”Embo Journal,Dec. 1990, pp. 3867-3874.
Moonen Peter
Reutelingsperger Christiaan Peter Maria
Vermaire Ad
Carlson Karen
Foley & Lardner LLP
Mosamedix B.V.
Talapatra Sunit
Villacorta Gilberto M.
LandOfFree
Annexin derivatives suitable for pretargeting in therapy and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Annexin derivatives suitable for pretargeting in therapy and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Annexin derivatives suitable for pretargeting in therapy and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4287108